The U.S. Food and Drug Administration has granted accelerated approval to Jideytro (zidesamtinib), a targeted therapy for a rare form of lung cancer, handing GSK its first approved lung cancer medicine just one week after the British drugmaker closed a $10.6 billion acquisition to acquire it.
The approval, announced July 22, 2026, covers adults with metastatic non-small cell lung cancer (NSCLC) whose tumors carry alterations in the ROS1 gene and who have already been treated with another therapy. It arrived nearly two months ahead of the FDA's September 18 decision deadline — a pace GSK attributes to the drug's breakthrough therapy and orphan drug designations.
A small patient group with few good options
ROS1 gene alterations drive only about 2% of non-small cell lung cancers. But because lung cancer is so common worldwide — roughly 50,000 people are diagnosed with ROS1-positive disease each year globally — even a narrow slice represents thousands of patients who currently cycle through a limited set of treatments.
Zidesamtinib was originally developed by Nuvalent, the biotech GSK acquired in a deal that ranks as its largest in eight years. According to the company, the drug is designed to work for longer, produce fewer side effects, and remain effective against resistance mutations that can blunt existing ROS1 inhibitors over time. Those are manufacturer claims tied to the drug's accelerated approval, which the FDA typically grants on early evidence while requiring follow-up trials to confirm long-term benefit.
Entering a competitive field
Jideytro joins a market already served by Pfizer's Xalkori and Roche's Rozlytrek, both approved for ROS1-positive lung cancer. GSK is betting that better durability and resistance coverage will help its new medicine stand out for patients whose cancer has progressed on those earlier options.
"The rapid progression of Jideytro from development to approval reflects both the strength of the underlying science and the urgent need for additional effective and tolerable treatments for ROS1-positive lung cancer," said Tony Wood, GSK's Chief Scientific Officer.
The Nuvalent purchase brought GSK more than a single product. The same transaction included neladalkib, another cancer drug currently under FDA review, signaling that the company's push into oncology — a years-long strategic priority — is likely to continue.
What this means for patients
For someone living with ROS1-positive lung cancer whose current treatment has stopped working, an additional approved option matters. A new drug in this class can offer another line of therapy when resistance develops — often the point at which choices run out.
That said, accelerated approval is not the final word. It allows a promising drug to reach patients sooner, but the FDA still expects confirmatory data down the line, and real-world results can differ from early trials. Anyone weighing a new therapy should discuss its risks, benefits, and evidence with their oncologist rather than relying on a drug's newness alone.